Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5132 in Advanced Solid Tumors
NCT06932094Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS5132 in solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Qilu Pharmaceutical. Primary endpoints: Incidence and severity of adverse events and serious adverse events up to 2 years, Maximum tolerated dose at 28 days and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
QLS5132
03
Conditions
solid tumorovarian cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06932094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932094.